This inventor holds 2 USPTO granted patents. Top assignee: Cho Pharma Inc.. Active years: 2021-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021-2023
Title: Charng-Sheng Tsai: Innovator in Antibody-Drug Conjugates
Introduction
Charng-Sheng Tsai is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of biotechnology, particularly in the development of antibody-drug conjugates. With a total of 2 patents, his work is recognized for its potential impact on therapeutic applications.
Latest Patents
Tsai's latest patents focus on antibody-drug conjugates (ADCs). One of his notable inventions describes an ADC with a specific structure represented by Formula (I): a pharmaceutically acceptable salt thereof wherein Ab is an antibody without glycans. The invention details various moieties, including glycan, conjugation, and linker moieties, which may vary in composition. Another patent also elaborates on an ADC structure, emphasizing the unique combination of drug units and their configurations.
Career Highlights
Charng-Sheng Tsai is currently associated with Cho Pharma Inc., where he continues to innovate in the field of drug development. His expertise in antibody-drug conjugates positions him as a key player in advancing therapeutic solutions.
Collaborations
Tsai has collaborated with notable colleagues, including Nan-Horng Lin and Ting-Chun Hung. Their combined efforts contribute to the ongoing research and development in the biotechnology sector.
Conclusion
Charng-Sheng Tsai's work in antibody-drug conjugates showcases his innovative spirit and dedication to advancing medical science. His contributions are paving the way for new therapeutic options in the treatment of various diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile